Sumitomo Dainippon Pharma Co. Ltd., of Osaka, Japan, reported top-line results from a phase III trial testing Parkinson's disease candidate Trerief (zonisamide) in patients with Parkinsonism in dementia with lewy bodies (DLB), which met the primary endpoint.